Curran Terrie
Director at ARQT; President and Chief Executive at PHAT; Director at Myovant Sciences Ltd., and 1 more
- Sold, on record
- $5M
- Dollars the filings state
- Form 4 sales
- 14
- Latest Aug 27, 2026
- Form 144 notices
- 1
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- ARQTArcutis Biotherapeutics, Inc.Director
- PHATPhathom Pharmaceuticals, Inc.President and Chief Executive
- Myovant Sciences Ltd.Director
- CELGENE CORP /DE/Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- PHAT90,104 shares
- Myovant Sciences Ltd.53,358 shares
- ARQT47,959 shares
- CELGENE CORP /DE/13,065 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale PHATPlan not statedMar 1, 2023 2023
Sold 1,436 shares at $8.54 ($12k)
Curran Terrie, President and Chief Executive
Sold 0.8% of holdings ($1.5M position)175,371 shares left0.2x usual sizeFiling
- 2 Form 4 sale PHATUnusualMar 22, 2024 +387 days
Sold 16,851 shares at $9.11 ($154k)
Curran Terrie, President and Chief Executive
No 10b5-1 planSold 3.9% of holdings ($3.9M position)410,784 shares left11x usual sizeFiling
- 3 Form 4 sale PHATUnusualJul 15, 2024 +115 days
Sold 33,848 shares at $11.72 ($397k)
Curran Terrie, President and Chief Executive
No 10b5-1 planSold 8.2% of holdings ($4.8M position)377,734 shares left9.2x usual sizeFiling
- 4 Form 144 notice ARQTNoticeNov 11, 2024 +119 days
Filed to sell 8,687 shares ($94k)
Curran Terrie, Director
No 10b5-1 planFirst sale on recordFiling
- 5 Form 4 sale ARQTUnusualNov 11, 2024 same day
Sold 8,687 shares at $10.85 ($94k)
Curran Terrie, Director
No 10b5-1 planSold 46.1% of holdings ($204k position)10,139 shares leftFirst sale on recordFollows a Form 144Filing
- 6 Form 4 sale PHATNo planJan 21, 2025 +71 days
Sold 19,109 shares at $6.59 ($126k)
Curran Terrie, President and Chief Executive
No 10b5-1 planSold 5% of holdings ($2.5M position)360,465 shares left1.1x usual sizeFiling
- 7 Form 4 sale ARQTNo planAug 20, 2026 +576 days
Sold 1,072 shares at $26.04 ($28k)
Curran Terrie, Director
No 10b5-1 planSold 4.4% of holdings ($641k position)23,526 shares leftFiling
- 8 Form 4 sale ARQTUnusualAug 27, 2026 +7 days
Sold 38,200 shares at $25.03 ($956k)
Curran Terrie, Director
No 10b5-1 planSold 61.9% of holdings ($1.5M position)23,526 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (15)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Aug 28, 2026 | ARQT | Director | Form 4 sale | 38,200 | $956k | 61.9% | Unusual | SEC |
| Aug 20, 2026 | Aug 24, 2026 | ARQT | Director | Form 4 sale | 1,072 | $28k | 4.4% | No plan | SEC |
| Jan 21, 2025 | Jan 23, 2025 | PHAT | President and Chief Executive | Form 4 sale | 19,109 | $126k | 5.0% | No plan | SEC |
| Nov 11, 2024 | Nov 13, 2024 | ARQT | Director | Form 4 sale | 8,687 | $94k | 46.1% | Unusual | SEC |
| Nov 11, 2024 | Nov 12, 2024 | ARQT | Director | Form 144 notice | 8,687 | $94k | Notice | SEC | |
| Jul 15, 2024 | Jul 17, 2024 | PHAT | President and Chief Executive | Form 4 sale | 33,848 | $397k | 8.2% | Unusual | SEC |
| Mar 22, 2024 | Mar 26, 2024 | PHAT | President and Chief Executive | Form 4 sale | 16,851 | $154k | 3.9% | Unusual | SEC |
| Mar 1, 2023 | Mar 3, 2023 | PHAT | President and Chief Executive | Form 4 sale | 1,436 | $12k | 0.8% | Plan not stated | SEC |
| Jan 20, 2023 | Jan 20, 2023 | PHAT | President and Chief Executive | Form 4 sale | 5,821 | $48k | 3.2% | Plan not stated | SEC |
| Nov 21, 2022 | Nov 23, 2022 | PHAT | President and Chief Executive | Form 4 sale | 1,526 | $15k | 1.8% | Plan not stated | SEC |
| Sep 9, 2021 | Sep 13, 2021 | Myovant Sciences Ltd. | Director | Form 4 sale | 4,850 | $124k | 100.0% | Unusual | SEC |
| Sep 2, 2021 | Sep 3, 2021 | Myovant Sciences Ltd. | Director | Form 4 sale | 48,508 | $1.2M | 100.0% | Unusual | SEC |
| Mar 22, 2021 | Mar 23, 2021 | PHAT | President and Chief Executive | Form 4 sale | 11,513 | $499k | 100.0% | Unusual | SEC |
| Sep 18, 2019 | Sep 19, 2019 | CELGENE CORP /DE/ | Officer | Form 4 sale | 11,338 | $1.1M | 84.0% | Unusual | SEC |
| Sep 25, 2017 | Sep 26, 2017 | CELGENE CORP /DE/ | Officer | Form 4 sale | 1,727 | $248k | 30.6% | Unusual | SEC |